New York State Common Retirement Fund Immuneering Corp Transaction History

New York State Common Retirement Fund

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$1.28 - $2.75 $12,108 - $26,015	-9,460 Reduced 97.84%	209 $0
Q1 2024 May 07, 2024	BUY	$1.91 - $7.32 $1,096 - $4,201	574 Added 6.31%	9,669 $28,000
Q4 2023 Feb 01, 2024	SELL	$4.84 - $8.44 $198 - $346	-41 Reduced 0.45%	9,095 $67,000
Q3 2023 Nov 07, 2023	BUY	$7.21 - $10.68 $1,701 - $2,520	236 Added 2.65%	9,136 $70,000
Q2 2023 Aug 07, 2023	BUY	$6.49 - $13.36 $57,761 - $118,904	8,900 New	8,900 $90,000
Q2 2022 Aug 04, 2022	SELL	$3.89 - $7.81 $17,396 - $34,926	-4,472 Reduced 96.44%	165 $1,000
Q4 2021 Feb 02, 2022	BUY	$16.12 - $31.02 $47,344 - $91,105	2,937 Added 172.76%	4,637 $75,000
Q3 2021 Nov 02, 2021	BUY	$17.0 - $32.84 $28,900 - $55,828	1,700 New	1,700 $45,000

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $57.8M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.